Deep Longevity to Launch Accrua Telehealth Platform in US

Sep 28, 2026
Deep Longevity will launch Accrua in the United States in October 2026, offering clinician guided care based on biological age assessments from routine blood tests.

Regent Pacific says Deep Longevity will launch its Accrua consumer telehealth platform in the United States in October 2026, according to a press release. The company plans to make the service available across all 50 states.

Accrua uses Deep Longevity's BloodAge report, which analyzes a routine blood test to compare biological age with chronological age. After consulting a licensed US clinician, eligible users may receive treatments in areas including GLP-1 weight loss therapies, peptides, hormone replacement therapy and testosterone therapies. The platform plans to repeat BloodAge testing quarterly to track changes.

Independent licensed physicians, pharmacies, compounding partners and established telehealth infrastructure providers will handle consultations, prescriptions, fulfillment, intake and billing. Accrua will primarily use a recurring subscription model and operate on HIPAA compliant infrastructure.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.